The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ADS Program and Warrant Agent Agreement

27 Nov 2019 07:00

RNS Number : 7683U
Motif Bio PLC
27 November 2019
 

 

Motif Bio plc

("Motif Bio" or the "Company")

 

American Depositary Shares ("ADS") Program and Warrant Agent Agreement

 

Motif Bio plc (AIM/Nasdaq: MTFB) announces, that further to the announcement yesterday of the Company's intention to voluntarily delist its American Depository Shares (ADSs), it has given notice on November 26, 2019 to The Bank of New York Mellon to terminate its American Depositary Shares ("ADS") Program and Warrant Agent Agreement.

 

The Depositary will contact ADS holders in due course with additional information on this process, including those necessary and proper actions to be executed.

 

For further information please contact:

 

 

Motif Bio plc

ir@motifbio.com

Graham Lumsden (Chief Executive Officer)

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0)20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Abigail Wayne (Sales & Broking)

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/Lianne Cawthorne

motifbio@walbrookpr.com

MC Services AG (EUROPEAN IR)

+49 (0)89 210 2280

Raimund Gabriel

raimund.gabriel@mc-services.eu

 

 

Forward-Looking Statements

When used in this Press Release, the words or phrases "intends," "anticipates," "expected to be" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties including, but not limited to, changes in economic conditions in the Company's market area, changes in policies by regulatory agencies, fluctuations in interest rates, competition that could cause actual results to differ materially from historical earnings and those presently anticipated or projected, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company advises readers that the factors listed above could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revision which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKADBBBDBPDB
Date   Source Headline
7th Mar 201912:07 pmRNSSecond Price Monitoring Extn
7th Mar 201912:02 pmRNSPrice Monitoring Extension
19th Feb 20197:00 amRNSConference Call and Webcast
18th Feb 20197:00 amRNSAmendment Agreement with Hercules Capital
15th Feb 20194:28 pmRNSHolding(s) in Company
15th Feb 20194:26 pmRNSHolding(s) in Company
14th Feb 20197:00 amRNSComplete Response Letter from the FDA
5th Feb 20197:00 amRNSExercise of Warrants
23rd Jan 20194:31 pmRNSExercise of Warrants
1st Nov 20184:40 pmRNSSecond Price Monitoring Extn
1st Nov 20184:35 pmRNSPrice Monitoring Extension
31st Oct 20187:00 amRNSJefferies London Healthcare Conference
30th Oct 20184:35 pmRNSPrice Monitoring Extension
16th Oct 20184:40 pmRNSSecond Price Monitoring Extn
16th Oct 20184:35 pmRNSPrice Monitoring Extension
3rd Oct 20188:01 amRNSMotif Bio Presents New Iclaprim Data at IDWeek
28th Sep 20187:01 amRNSMotif Bio Notes Statement from Amphion Innovations
25th Sep 20187:00 amRNSHalf-year Report
20th Sep 20187:00 amRNSUpcoming Scientific Conferences
5th Sep 20187:00 amRNSIclaprim Data presented at ESCMID/ASM Conference
29th Aug 20184:35 pmRNSPrice Monitoring Extension
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
17th Aug 20187:00 amRNSIclaprim Data at ESCMID/ASM Conference
14th Aug 20184:49 pmRNSHolding(s) in Company
14th Aug 20184:48 pmRNSHolding(s) in Company
14th Aug 20187:00 amRNSFDA Acceptance of New Drug Application
9th Aug 20187:00 amRNSInvestor Events in August and September
8th Aug 20187:00 amRNSNotice of Allowance for Two U.S. Iclaprim Patents
2nd Aug 20184:35 pmRNSPrice Monitoring Extension
3rd Jul 20184:48 pmRNSHolding(s) in Company
3rd Jul 20187:00 amRNSDirectorate Change
26th Jun 201811:57 amRNSExercise of Stock Options
19th Jun 20181:58 pmRNSResult of AGM
14th Jun 20187:00 amRNSMotif Bio Submits NDA for Iclaprim
11th Jun 201811:41 amRNSHolding(s) in Company
11th Jun 20187:00 amRNSMotif Bio present New Iclaprim Data at ASM Microbe
8th Jun 20185:08 pmRNSHolding(s) in Company
31st May 20187:00 amRNSJefferies Global Healthcare Conference
25th May 20184:04 pmRNSHolding(s) in Company
24th May 20184:39 pmRNSHolding(s) in Company
23rd May 20185:42 pmRNSHolding(s) in Company
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
17th May 20182:24 pmRNSResult of Placing
17th May 20189:55 amRNSProposed Placing to raise approximately £10m
9th May 20187:00 amRNSAppointment of Vice President,Clinical Development
8th May 20187:00 amRNSMotif Bio to Present Iclaprim Data at ASM Microbe
1st May 20187:00 amRNSREVIVE-2 Study Results Published in Journal
19th Apr 20187:00 amRNSNew Iclaprim Data being Presented at ECCMID 2018
17th Apr 20184:40 pmRNSSecond Price Monitoring Extn
17th Apr 20184:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.